TY - JOUR
T1 - T-cell pediatric acute lymphoblastic leukemia: Analysis of survival and prognostic factors in 4 consecutive protocols of the Spanish cooperative study group SHOP
AU - Rives, Susana
AU - Estella, Jesús
AU - Camós, Mireia
AU - García-Miguel, Purificación
AU - Verdeguer, Amparo
AU - Couselo, José Miguel
AU - Tasso, María
AU - Molina, Javier
AU - Gómez, Pedro
AU - Fernández-Delgado, Rafael
AU - Navajas, Aurora
AU - Badell, Isabel
PY - 2012/7/7
Y1 - 2012/7/7
N2 - Background and objectives: Acute lymphoblastic leukemia (ALL) is the most frequent cancer in childhood, with cure rates of 80-85%. In T-cell ALL (15% of ALL), prognostic factors are ill defined. We aimed to describe the event-free survival (EFS) and analyze clinical prognostic factors in a series of pediatric T-ALL of 4 consecutive clinical trials. Patients and methods: Children with T-ALL aged 1-18 years treated in 37 institutions in Spain were enrolled in 4 consecutive trials from February-1989 to November-2009. Results: A total of 218 T-ALL patients out of 1,652 pediatric ALL were evaluable during the study period (SHOP/ALL-89: 35, ALL-94: 63, ALL-99: 62, ALL-2005: 58). There were 164 boys (75%). Median age (years) was 7.8 range (1.3-18.6). Median leukocytes (10 9/L) was 78.2, range 0.8-930. Fifteen (6.8%) children had central nervous system (CNS) involvement at diagnosis. Regarding response to induction treatment, 150 (75%) patients had less than 5% blasts on day-14 bone marrow and 199 achieved complete remission at the end of induction. Overall survival (OS) at 60 months for SHOP/ALL-89, ALL-94, ALL-99 was 48 (8), 49 (6), 70 (6) %, respectively, and at 48 months for SHOP/ALL-2005 (ongoing protocol) was 74 (8) %. Median follow-up (months) was 206, 152, 74 and 17 respectively. Analysis of prognostic factors revealed no statistical differences regarding sex or age. Leukocyte count over 200 × 109/l (P =.024), CNS infiltration at diagnosis (P <.006) and treatment response had prognostic significance (end-induction complete remission) (P =.0000), day 14-bone marrow (P =.005). Conclusions: Results for the SHOP/ALL-89 and ALL-94 protocols were inferior to other contemporary protocols but there has been an improvement in survival in the 2 last trials. In line with other T-ALL series, response to treatment had the strongest prognostic impact. © 2011 Elsevier España, S.L. All rights reserved.
AB - Background and objectives: Acute lymphoblastic leukemia (ALL) is the most frequent cancer in childhood, with cure rates of 80-85%. In T-cell ALL (15% of ALL), prognostic factors are ill defined. We aimed to describe the event-free survival (EFS) and analyze clinical prognostic factors in a series of pediatric T-ALL of 4 consecutive clinical trials. Patients and methods: Children with T-ALL aged 1-18 years treated in 37 institutions in Spain were enrolled in 4 consecutive trials from February-1989 to November-2009. Results: A total of 218 T-ALL patients out of 1,652 pediatric ALL were evaluable during the study period (SHOP/ALL-89: 35, ALL-94: 63, ALL-99: 62, ALL-2005: 58). There were 164 boys (75%). Median age (years) was 7.8 range (1.3-18.6). Median leukocytes (10 9/L) was 78.2, range 0.8-930. Fifteen (6.8%) children had central nervous system (CNS) involvement at diagnosis. Regarding response to induction treatment, 150 (75%) patients had less than 5% blasts on day-14 bone marrow and 199 achieved complete remission at the end of induction. Overall survival (OS) at 60 months for SHOP/ALL-89, ALL-94, ALL-99 was 48 (8), 49 (6), 70 (6) %, respectively, and at 48 months for SHOP/ALL-2005 (ongoing protocol) was 74 (8) %. Median follow-up (months) was 206, 152, 74 and 17 respectively. Analysis of prognostic factors revealed no statistical differences regarding sex or age. Leukocyte count over 200 × 109/l (P =.024), CNS infiltration at diagnosis (P <.006) and treatment response had prognostic significance (end-induction complete remission) (P =.0000), day 14-bone marrow (P =.005). Conclusions: Results for the SHOP/ALL-89 and ALL-94 protocols were inferior to other contemporary protocols but there has been an improvement in survival in the 2 last trials. In line with other T-ALL series, response to treatment had the strongest prognostic impact. © 2011 Elsevier España, S.L. All rights reserved.
KW - Pediatric
KW - Prognostic factors
KW - T-cell acute lymphoblastic leukemia
U2 - 10.1016/j.medcli.2011.12.019
DO - 10.1016/j.medcli.2011.12.019
M3 - Article
VL - 139
SP - 141
EP - 149
IS - 4
ER -
